Altman Peter 4

What Happened
Peter Altman, President, CEO and a director of BioCardia, acquired a total of 2,300 common shares in two open-market purchases: 1,500 shares on 2026-06-17 (weighted avg price $0.85, total ~$1,275) and 800 shares on 2026-06-18 (weighted avg price $0.96, total ~$768). Both transactions are reported as purchases (code P) — insider buys are often watched by investors as a potential bullish signal, though they do not prove future performance.

Key Details

• Transaction dates and prices:
  • 2026-06-17: 1,500 shares, weighted avg $0.85 (actual trades ranged $0.84–$0.89) — total ≈ $1,275. (Footnote F1)
  • 2026-06-18: 800 shares, weighted avg $0.96 (actual trades ranged $0.98–$0.96) — total ≈ $768. (Footnote F2)
• Aggregate: 2,300 shares purchased for about $2,043.
• Shares owned after the transactions: not specified in the information provided.
• Footnotes: the reported per-share prices are weighted averages across multiple trades; complete per-trade details are available upon request to the SEC staff or issuer per the filing footnotes.
• Timeliness: The filing (accession 0001437749-26-021216) was submitted on 2026-06-22. That appears to be late for the 6/17 trade (deadline would have been 2 business days after the transaction); the 6/18 trade’s 2-business-day window closed on 6/22, the filing date.

Context
These were straightforward open-market purchases (no option exercises, awards, or gifts). The dollar amounts are modest, so while it’s a buy by the company’s CEO, the purchases represent a small economic commitment rather than a large new stake.